Disease Landscape and Forecast 인사이트

Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market. Prescription treatment…

Acute heart failure (AHF) is characterized by the rapid onset or aggravation of symptoms of heart failure. The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a…

The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape, which has historically been dominated by…

Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus caused by an accumulation of eosinophils leading to a difficulty in swallowing food with the potential…

Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…

MARKET OUTLOOK Cutaneous lupus erythematosus (CLE) is a heterogeneous inflammatory autoimmune disease affecting the skin; discoid lupus erythematosus (DLE) is the most prevalent subtype of CLE…

Chronic sinusitis is prolonged inflammation of the paranasal sinuses that persists for more than 12 weeks despite treatment. Intranasal corticosteroids are typically used for treatment, followed by…

MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α)…

The highly entrenched generic market for major depressive disorder (MDD) patients poses a challenge for branded agents attempting to gain traction in the United States. The heterogeneous responses…

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…

Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract. Although OTC treatment for OIC is common…

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent…